The recently published trial in JAMA has suggested that the treatment with convalescent plasma in COVID-19 is feasible and can be used as a potential treatment option in this devastating pandemic.

In this episode, we discuss another landmark trial published in NEJM on the use of Remdesivir in COVID-19. This trial has raised more questions than providing answers.

In this podcast, we discuss multi-national registry data on the efficacy of chloroquine, hydroxychloroquine with or without macrolides in COVID-19 patients. This study has added significant information to our understanding of COVID-19 and has warned us against the use of the combination of HCQ and macrolides.

COVID-19 pandemic has posed a very difficult challenge to the entire ICU community i.e. how to prevent transmission to health care workers while performing routine interventions in critically ill patients. This has forced us to unlearn the traditional ways and learn new ways of performing certain interventions in ICU. In this podcast, we discuss specific modifications that every ICU staff need to be aware of while caring for COVID-19 patient.

Remdesisvir has thought to be the new CURE for COVID-19. In this podcast, we discuss the recent evidence available on the efficacy of Remdesivir in COVID-19.

The literature published from various countries has helped us to understand the disease pattern in COVID-19 pandemic. In this podcast, we discuss the key literature from New York, Italy, China and the UK.

In this episode, we summarise the key literature published in last week w.r.t novel therapies in COVID-19.

In this podcast, we discuss current controversies w.r.t treatment of COVID -19 patients and summarise the literature available till date.

In this podcast, we discuss how to manage critically ill patient diagnosed with COVID-19. This podcast based on current recommendations from various societies and the expressed views may change as recommendations change over time.

Vasopressor administration to maintain higher map in patients >65 years of age has become a dogma. In this podcast, we discuss recently published 65 trial which not only challenges this dogma but will definitely change our practices.